TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04052698
Drug: Wilate
Normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute.
Study: NCT00274885
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000334
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00805155
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study: NCT00805155
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study: NCT00805155
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Study: NCT02111850
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study: NCT04815395
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of oxytocin (24IU) orally
Study: NCT04815395
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of oxytocin (24IU) intranasally
Study: NCT01269450
Drug: micronized progesterone 200 mg (Utrogestan)
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
Study: NCT03664050
Drug: group A 2.5 mg letrozole oral tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
Study: NCT04620720
Drug: capule gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neuropathic analgesic
Study: NCT01522950
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg daily or 10 mg daily
Study: NCT01522950
Drug: atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg daily or 50 mg daily
Study: NCT02582372
Drug: Dexmedetomidine and bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
Study: NCT02582372
Drug: Fentanyl and bupivacaine
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
Study: NCT03421366
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
Study: NCT04203160
Drug: CPI 613
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously
Study: NCT01082406
Drug: catridecacog
Normalized name: Catridecacog
DrugBank: Catridecacog (DB09310)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
Study: NCT04203160
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously
Study: NCT04203160
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously
Study: NCT01082406
Drug: recombinant factor XIII
Normalized name: Recombinant Factor XIII (human)
DrugBank: Recombinant Factor XIII (human) (DB17729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
Study: NCT01207440
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib tablets.
Study: NCT00110188
Drug: ridaforolimus
Normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01333072
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
Study: NCT01333072
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
Study: NCT03121014
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
Study: NCT03121014
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: targeting a 4800μM/min/ day from day -5 through day -2
Study: NCT03121014
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
Study: NCT03121014
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
Study: NCT01386502
Drug: CT-011
Normalized name: CT-011
DrugBank: CT-011 (DB05916)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03363477
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03363477
Drug: Clexane
Normalized name: Clexane
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03907800
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
Study: NCT03907800
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
Study: NCT03907800
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In case of HER2-positive, patients receive Herceptin weekly during all cycles.
Study: NCT01701037
Drug: dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg given PO
Study: NCT01701037
Drug: trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg given PO
Study: NCT00412737
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
Study: NCT03042468
Drug: 177Lu-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
Study: NCT03042468
Drug: 68Ga-PSMA-HBED-CC
Normalized name: 68Ga-Psma-hbed-CC
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
Study: NCT02740920
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04685694
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sl 800 mcg misoprostol
Study: NCT00002829
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously on Day -8
Study: NCT00002829
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beginning 1 hour after initiation of the cyclophosphamide treatment.
Study: NCT00356824
Drug: Amodiaquine
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
Study: NCT00356824
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
Study: NCT01575717
Drug: Vitamin D3 4000 IU
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
Study: NCT01575717
Drug: Vitamin D3 2000 IU
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
Study: NCT04039919
Drug: Padsevonil
Normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padsevonil will be administered in predefined dosages.
Study: NCT01882179
Drug: Mineralocorticoid receptor antagonist potassium-canrenoate
Normalized name: potassium canrenoate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01091103
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03570450
Drug: Adipose derived Stem Cell
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses
Study: NCT01675024
Drug: Rotigotine, Period 1
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3
Study: NCT01675024
Drug: Rotigotine, Period 2
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3
Study: NCT02760264
Drug: Vamorolone 0.25 mg/kg/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 0.25 mg/kg/day daily for 14 days.
Study: NCT02760264
Drug: Vamorolone 0.75 mg/kg/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 0.75 mg/kg/day daily for 14 days.
Study: NCT02760264
Drug: Vamorolone 2.0 mg/kg/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 2.0 mg/kg/day daily for 14 days.
Study: NCT02760264
Drug: Vamorolone 6.0 mg/kg/day
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 6 mg/kg/day daily for 14 days.
Study: NCT00983918
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
Study: NCT00983918
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
Study: NCT00983918
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
Study: NCT00983918
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
Study: NCT00832221
Drug: SEROQUEL XR (quetiapine)
Normalized name: quetiapine Extended Release Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeated dose of oral tablets, 8 times per subject
Study: NCT00832221
Drug: SEROQUEL IR (quetiapine)
Normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeated dose of oral tablets, 4 times per subject
Study: NCT00832221
Drug: radioligand [11C]raclopride
DrugBank: Raclopride (DB12518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of iv admin, 5 times per subject
Study: NCT03135899
Drug: BI 443651
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, each 12 hours apart
Study: NCT03995017
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib tablet
Study: NCT03995017
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab intravenous solution
Study: NCT03995017
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab intravenous solution
Study: NCT02139618
Drug: Methyl Aminolevulinate (MAL)
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03914118
Drug: Preoperative modafinil + postoperative placebo
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg modafinil pre-operatively and placebo immediately post-operatively.
Study: NCT03914118
Drug: Preoperative modafinil + postoperative modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
Study: NCT01679197
Drug: Metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02450877
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00255151
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
Study: NCT00255151
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
Study: NCT02130167
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
Study: NCT02317679
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
Study: NCT04358133
Drug: Chlorhydrate de morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
Study: NCT03954756
Drug: Apatinib and PD1
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
Study: NCT02130531
Drug: Emixustat HCl Tablet
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Emixustat (DB12608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT04776746
Drug: trofinetide
Normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
Study: NCT02507440
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
Study: NCT02507440
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive intravenous propofol as anesthesia for EGD
Study: NCT03392740
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
Study: NCT03915496
Drug: PF-04965842 200 mg
Normalized name: acetylcysteine
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT03915496
Drug: PF-04965842 100 mg
Normalized name: PF-04965842
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT00563017
Drug: Long-acting Risperidone microspheres injection
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02783430
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
Study: NCT02783430
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
Study: NCT02663674
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
Study: NCT00602706
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00512707
Drug: Sildenafil citrate (open label)
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
Study: NCT00477971
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00477971
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or orally
Study: NCT01820858
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m(2), intravenously (IV)
Study: NCT01820858
Drug: Paraplatin (Carboplatin Injection)
Normalized name: carboplatin Injectable Solution [Paraplatin]
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5, IV